ASH 2021 | Phase I trial of plamotamab in r/r NHL
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, discusses preliminary findings from a Phase I dose-escalation trial (NCT02924402) of plamotamab, a bispecific antibody that binds both CD20 and CD3, in heavily pre-treated patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL). Patients either received a weight-based or flat dose. Plamotamab demonstrated promising clinical activity and patients on a flat dose regimen reported less severe cases of cytokine release syndrome (CRS). This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Transcript (edited for clarity)
So plamotamab is a CD3, CD20 bispecific antibody currently being studied in a Phase I study of B-cell non-Hodgkins lymphoma patients. So we presented data on the safety and efficacy of two cohorts. One was weight-based dosing strategy and the second was a cohort of patients with flat dosing after a period of step up, and the flat dosing will be moving forward as the recommended Phase II dosing. So we’re reporting safety outcomes and efficacy for those patients that have been treated thus far...
So plamotamab is a CD3, CD20 bispecific antibody currently being studied in a Phase I study of B-cell non-Hodgkins lymphoma patients. So we presented data on the safety and efficacy of two cohorts. One was weight-based dosing strategy and the second was a cohort of patients with flat dosing after a period of step up, and the flat dosing will be moving forward as the recommended Phase II dosing. So we’re reporting safety outcomes and efficacy for those patients that have been treated thus far.
What we see in the overall cohort is a low rate of high-grade CRS. And so if we take all patients in the weight based cohort, that incidence was low. In the flat based dosing, we actually didn’t see any Grade 3 or 4 CRS, it was all Grade 1 and Grade 2, and primarily in the first dose. And so that’s a very, I think, promising platform to develop as the recommended Phase II dose.
Read more...
